LONDON (Thomson Financial) - Inhaler manufacaturer Consort Medical Plc has
announced full-year pretax profits from operations 7.3 million pounds, levelling
to 17.6 million before exceptional items, compared with 15.6 million last year.
The company, formerly known as Bespak, was forced to close down a factory
after was being hit last year by the unexpected cancellation of a contract to
supplier inhalers to Pfizer Inc for its Exubera insulin product.
Consort announced full-year adjusted EPS up 1 percent to 44.8 pence/share vs
44.3 pence/share, and a final dividend flat at 12.1 pence/share.
It also announced the appointment of Toby Woolrych as its new group finance
director.
Chief executive Jon Glenn said in a statement the company was now on a "a
sound footing with long-term contracts".
ben.deighton@thomsonreuters.com
bsd
COPYRIGHT
Copyright Thomson Financial News Limited 2008. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|